OTCPicks.com Stocks to Watch for Friday, October 5th
OTCPicks Publisher Newsletter
OTCPicks.com Stocks to Watch for Friday, October 5th CYOE, IFIX, ESMC, CLRX, ALZM, EVDR Our Stocks to Watch tomorrow include Cytocore Inc. (OTCBB: CYOE), Internal Fixation Systems Inc. (OTCBB: IFIX), Escalon Medical Corp. (Nasdaq: ESMC), CollabRx Inc. (Nasdaq: CLRX), Allezoe Medical Holdings Inc. (OTCBB: ALZM) and Evader Inc. (OTC: EVDR).
Visit http://otcpicknews.com/emailmarketer/link.phpM940&N77&L1&F=T to register for our Stocks to Watch Newsletter and Email Stock Watch Alerts.
CYTOCORE INCORPORATED (OTCBB: CYOE) “Up 212.82% on Thursday” Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N77&L58&F=T Cytocore, Inc. develops, manufactures, and sells an integrated family of products for the detection, diagnosis, and treatment of cancer under the CytoCore Solutions trade name. The companys CytoCore Solutions products focus on addressing sample collection; specimen preparation; specimen evaluation, including detection/screening, and diagnosis; and treatment and patient monitoring related to specific cancers. Its cell collection devices include SoftPAP, a device for the collection of cervical cell samples that are used in the detection of cervical dysplasia, cancer, and human papillomavirus infections; and PadKit, a sample collection device that ensures female reproductive tract health. The company is also developing stains and reagents for use in cervical cytology and other screening applications, as well as cell preservatives for cytological applications.
In addition, it focuses on developing specimen evaluation products, such as AIPS workstation to address the root causes of various ergonomic problems; and AIPS Imager, a medical screening program to differentiate between patients who show no evidence of the target disease state and those who do, as well as developing a derivative of the SoftPAP cell collection device to apply a patch containing a therapeutic agent to the cervix. The company was formerly known as Molecular Diagnostics, Inc. and changed its name to Cytocore, Inc. in June 2006. Cytocore, Inc. is based in Chicago, Illinois.
CYOE News:
No recent news for Cytocore, Inc. (OTCBB: CYOE).
INTERNAL FIXATION SYSTEMS INCORPORATED (OTCBB: IFIX) “Up 11.76% on Thursday” Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N77&L71&F=T Internal Fixation Systems, Inc. engages in the manufacture, marketing, and sale of orthopedic, podiatric, and spinal implants. The company offers mini to large cannulated screw systems that are used for bone fixation; locking plate and screw systems, which are used to treat fractures in the ankle, wrist, elbow, clavicle, shoulder, foot, forearm, pelvis, tibia, and hip, as well as has trauma applications; and external fixators. It also sells K-wires and drill bits that are used to implant its products. The company serves ambulatory surgery centers, hospitals, surgeons, and group purchasing organizations. Internal Fixation Systems, Inc. was founded in 2006 and is headquartered in Medley, Florida.
IFIX News:
No recent news for Internal Fixation Systems, Inc. (OTCBB: IFIX).
ESCALON MEDICAL CORPORATION (NASDAQ: ESMC) “Up 148.72% on Thursday” Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N77&L09&F=T Escalon Medical Corp., together with its subsidiaries, engages in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the areas of ophthalmology, diabetes, hematology, and vascular access. It provides instruments for blood cell counting and blood analysis; and supplies the reagent and other consumable materials needed to operate the instruments. The company also sells diabetic testing products, including DS5 that measures long-term glucose control in diabetic patients; and Hb-Gold, which provides for the in-vitro measurement of certain genetic diseases of the blood. In addition, Escalon Medical Corp.
offers equipment for use in the field of human and veterinary hematology.
Further, it develops, manufactures, and markets ultrasound systems for diagnostic or biometric applications in ophthalmology, including A-scans, B-scans, high frequency B-scans, and pachymeters. Additionally, the company offers vascular access products, including PD Access and SmartNeedle lines of monitors, and Doppler-guided bare needles and infusion needles that are used to locate desired vessels for access, as well as provides VascuView Visual ultrasound system. It also markets a Color/Fluorescein Angiography digital imaging system for ophthalmology; offers ophthalmic surgical products to vitreoretinal ophthalmic surgeons; distributes intraocular gas products, including C3F8 and SF6, which are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery; provides light sources, fiber optic probes, and illuminated tissue manipulators; and markets viscous fluid transfer systems and related disposable syringe products. Escalon Medical Corp. sells its products through internal sales employees, independent sales representatives, and distributors to medical institutions, teaching institutions, hospitals, and eye surgery centers in the United States and Europe. The company was founded in 1987 and is based in Wayne, Pennsylvania.
ESMC News:
October 4 – Escalon Medical Corp. Sells Its Clinical Diagnostics Business Escalon Medical Corp. (Nasdaq: ESMC) (the “Company”) today announced the sale of its Clinical Diagnostics Business to ERBA Diagnostics, Inc. (NYSE:
ERB).
The Escalon Clinical Diagnostics Business (“ECD`) consists of Drew Scientific, Inc., and its wholly owned subsidiaries JAS Diagnostics, Inc.
(“JAS”) and Drew Scientific Limited Co. ECD develops and sells A1c and Hematology diagnostic instruments, reagents and chemistries. Drew was focused on providing instrumentation and consumables for the physician office labs, small hospital labs and veterinary research laboratories. Drew also supplies the reagent and other consumable materials needed to operate the instruments. JAS specializes in the manufacture of a broad range of liquid stable, diagnostics chemistry reagents used in IVD tests. Many of these reagents are single vial stable, which offer ease of use, increased speed of results and extended on-board stability. The sales price was $6,500,000 in cash.
The Company acquired Drew in 2004. Since the Company`s entry into the clinical diagnostics business, the Company`s strategic objective had been to expand our presence in the reagent segment of the IVD market. Drew was focused on the equipment side of the IVD business; JAS synergistically expanded the Company`s position into the clinical chemistry consumable market. The Company restructured the business in an effort to position it for profitability. As the path to profitability was longer than anticipated, the Company continued to invest into the business. Management realized that further investment and focus was needed to move ECD into profitability. Therefore, as the opportunity to seek strategic partners developed into opportunities for combinations, management pursued the opportunity presented by ERBA Diagnostics. ERBA Diagnostics develops, manufactures and markets proprietary diagnostic reagents, instrumentation and software, specializing in a full range of products from ERBA international group of companies in USA, Italy, Czech Republic, India and Turkey, including not only the Autoimmune and Infectious Elisa product lines, but also the full line of biochemistry, clinical chemistry and urine analysis products.
“The sale of Escalon Clinical Diagnostics business was based on the continuing extensive strategic evaluation and enables us to better focus our efforts and resources on our Ophthalmic business” said Richard J.
DePiano, Jr., President of Escalon. “We expect to use the cash we receive in the transaction to strengthen our balance sheet, to provide additional working capital, enhance our ability to strategically expand our Ophthalmic business and provide the means to selectively pursue opportunities for synergistic growth.” Escalon Clinical Diagnostics revenues from operations were $12,985,000, $13,708,000 and $18,077,000, in fiscal 2012, 2011, 2010, respectively. The sale of this business will have a material effect on earnings in subsequent periods.
Since 1997, the Company has acquired selective business`s or product lines with a mission to enhance or expand such for the sole purpose of creating shareholder value. During this time the Company has acquired six separate businesses or product lines and has divested of five. Each divesture provided Escalon with a stronger balance sheet and provided additional working capital, both of which enable it to grow its business.
COLLABRX INCORPORATED (NASDAQ: CLRX) “Up 37.99% on Thursday” Detailed Quote: www.otcpicks.com/quotes/CLRX.php CollabRx, Inc. (CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the worlds knowledge on genomics-based medicine with specific insights from the nations top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
CLRX News:
October 3 – CollabRx Partners with Life Technologies in Molecular Diagnostics CollabRx, Inc. (Nasdaq: CLRX) announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies global cancer diagnostics development and its laboratory developed test services business. The agreement represents a major step forward by CollabRx in providing laboratories and next-generation sequencing (NGS) companies with meaningful insights into cancer.
Molecular analysis, including genetic sequencing, is increasingly becoming an important part of the clinical management of cancer patients, said James Karis, Co-CEO of CollabRx. However, the sheer volume and complexity of genetic data that is being produced, particularly in the course of therapy development, is outpacing the ability of practicing physicians to stay current, and more importantly understand how to apply this genetic data in treating their patients.
CollabRx, Inc., a data analytics company focused on genomics, bridges this knowledge gap using cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the worlds knowledge on molecular medicine with specific insights from the nations top clinical experts.
Life Technologies will use CollabRx proprietary content and technology to pair the results of broad molecular profiling panels developed by Life Technologies with associated clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRxs large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the context engine for informing healthcare decision-making.
Its critical to contextualize the results of complex cancer panels to make them useful for interpreting and treating physicians, said Ronnie Andrews, president of Medical Sciences at Life Technologies. CollabRx has pioneered the development of a scalable platform and process to provide actionable, accessible, and credible knowledge at the point of care to aid physicians in developing a cancer treatment plan based on tumor molecular profiles. We are excited to include this key capability with our molecular diagnostic tests.
As the genomics revolution continues to unfold, successful cancer diagnostic companies will need cutting-edge technologies as well as deep, personalized analytics, said Thomas Mika, Co-CEO of CollabRx. We are thrilled to be a part of Life Technologies strategy to establish a leadership position in the clinical diagnostics market by providing ordering physicians with clinically relevant interpretation of test results, personalized for each patient, as a seamless part of the reporting process via Web-based and mobile technologies.
ALLEZOE MEDICAL HOLDINGS INCORPORATED (OTC: ALZM) “Up 10.00% on Thursday” Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N77&L70&F=T Allezoe Medical Holdings, Inc. is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations.
ALZM News:
No recent news for Allezoe Medical Holdings (OTCBB: ALZM).
EVADER INCORPORATED (OTC: EVDR) “Up 50.00% on Thursday” Detailed Quote:
http://otcpicknews.com/emailmarketer/link.phpM940&N77&L17&F=T Through its subsidiary Avtar Singh Construction Company (ASCC), Evader, Inc. is one of India`s largest builders.
EVDR News:
September 18 – Evader (EVDR) Corporate Affairs-CEO Message Evader, Inc. (OTC: EVDR), developer of robotic devices for security and medical applications is pleased to provide this EVDR management message to its followers and shareholders.
Eli Goldstein CEO of EVDR said, “I wish to take this opportunity on behalf of all EVDR management to express our gratitude and the patience EVDR followers and shareholders have shown over the last several months, and since Dr. Robot merger into EVDR. On a Corporate level our share structure remains unchanged and undisturbed.
EVDR is a vibrant young company which we hope to monetize upon and hopefully our hard work and efforts will reflect in the EVDR share price as the market place. Lastly to summarize and address our critics other concerns that EVDR product is sub standard to Japanese models at a far less price. To that end, we make this open challenge and invitation to our critics to come forward as we would welcome a full comparison in public of any similar competitor product to that of EVDR, especially integration with medical and security environment. EVDR robotics is not a standalone robot, it is an integrated platform which can adjust reaction based on outside sensors and events, and it is event driven, object oriented environment which is rarely available through our competitors. Simply put our Dr. Robot is flat out better hands down on all aspects of comparison.” The company is pleased to report that it has completed filings with OTC Markets of its financial statements Sep 7, 2012 and Quarterly Report Jun 30, 2012.
EVDR is not currently reporting to the SEC however the Company is uploading reports through the OTC Disclosure Filing Service, and other alternative reporting sources and means.
More details will follow via news releases and filings on OTC Markets.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N77&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N77&L=8&F=T.
Disclosure: OTCPicks.com is not currently being compensated by any of the companies covered in this release.
Related posts:
- OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, October 4th
- OTCPicks.com Daily Market Movers Digest Midday Report for Monday, May 23rd
- OTCPicks.com Daily Market Movers Digest Midday Report for Friday, June 3rd
- OTCPicks.com Stocks to Watch for Monday, June 6th
- OTCPicks.com Stocks to Watch for Thursday, August 23rd